Trade-offs between overall survival and side effects in the treatment of metastatic breast cancer: eliciting preferences of patients with primary and metastatic breast cancer using a discrete choice experiment.
Alistair BullenMandy RyanHolly EnnisEwan GrayLuis Enrique Loría-RebolledoMorag McIntyrePeter HallPublished in: BMJ open (2024)
Patients are willing to forgo overall survival to avoid particular severity levels of side effects. Our results have implications for data collected in research studies and can help inform person-centred care and shared decision-making.
Keyphrases
- metastatic breast cancer
- end stage renal disease
- ejection fraction
- healthcare
- newly diagnosed
- palliative care
- peritoneal dialysis
- prognostic factors
- free survival
- electronic health record
- big data
- patient reported outcomes
- machine learning
- pain management
- data analysis
- patient reported
- case control
- health insurance
- artificial intelligence